logo
Plus   Neg
Share
Email

AstraZeneca : Selumetinib Granted Orphan Drug Designation In Japan For Neurofibromatosis Type 1

AstraZeneca (AZN.L,AZN) said that selumetinib has been granted orphan drug designation in Japan for the treatment of neurofibromatosis type 1 or NF1, a rare and debilitating genetic disease.

Selumetinib is co-developed and co-commercialised with Merck & Co.

The National Cancer Institute Cancer Therapy Evaluation Program-sponsored Phase I/II SPRINT Stratum 1 trial showed an overall response rate of 66% in paediatric patients with NF1 PN when treated with selumetinib as a twice-daily oral monotherapy.

Overall response rate is defined as the percentage of patients with confirmed complete or partial response of at least 20% reduction in tumour volume.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..." Novartis AG (NVS) agreed to pay $678 million to settle U.S. government charges it paid illegal kickbacks to doctors to induce them to prescribe its cardiovascular and diabetes drugs, the U.S. Department of Justice said in a statement. PG&E Corp. (PCG) said Wednesday that it has emerged from Chapter 11 bankruptcy protection, after implementing its financial restructuring plan that was previously approved by the U.S. Bankruptcy Court and state regulators.
Follow RTT